A Double-Blind, Placebo-Controlled, Randomized, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-54861911 in Healthy Elderly Subjects
Phase of Trial: Phase I
Latest Information Update: 05 Mar 2018
Price : $35 *
At a glance
- Drugs Atabecestat (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions
- Sponsors Janssen Research & Development
- 05 Mar 2018 Results of analysis assessing potential QT effects of JNJ-54861911 using patient data from NCT01827982, NCT02152332 and NCT01887535 trials published in the Journal of Clinical Pharmacology
- 13 Jan 2014 According to ClinicalTrials.gov, the status changed from active no longer recruiting to completed.
- 27 Aug 2013 Planned number of patients changed from 40 to 62 as reported by ClinicalTrials.gov.